Skip to main content
. 2016 Mar 21;34(20):2359–2365. doi: 10.1200/JCO.2015.63.1960

Fig A4.

Fig A4.

Exploratory analysis of (A) time to first progression and (B) 2-year overall survival among patients with ER-positive/HER2-negative de novo stage IV breast cancer treated with first-line chemotherapy (n = 20). ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; RS, Recurrence Score.